AB
Ambrosia Biosciences at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Ambrosia Biosciences brings 2 presentations to ObesityWeek 2026 in National Harbor. Its program centres on the discovery of oral small molecule drugs for obesity. It covers AMB-895, a long-acting GLP-1 receptor agonist, and the nonclinical profile of AMB-131, a GIP receptor antagonist.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
AB Ambrosia Biosciences | |
Drug developer working on oral small-molecule GLP-1 and GIP receptor agonists for obesity. | Poster Sun Nov 15 2:30pm–3:30pm Discovery of AMB-895, a Long-Acting and Novel, Oral Small Molecule GLP-1 Receptor Agonist Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Discovery and Nonclinical Profile of AMB-131, a Novel, Oral Small Molecule GIP Receptor Antagonist Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Find decision makers at Ambrosia Biosciences
Tell us what you sell and we’ll find the people at Ambrosia Biosciences most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction